Access cutting-edge colorectal cancer treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.
Access colorectal cancer specialists in Kansas City at no cost
This study follows strict safety protocols and ethical guidelines
All study-related colorectal cancer treatment provided free
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatmen
Sponsor: AbbVie
Check if you qualify for this colorectal cancer clinical trial in Kansas City, MO
If you're searching for colorectal cancer treatment options in Kansas City, MO, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.